Jeff Yass’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-209,309
| Closed | -$1.49M | – | 9737 |
|
|
2016
Q2 | $1.12M | Buy |
209,309
+190,518
| +1,014% | +$977K | ﹤0.01% | 4639 |
|
|
2016
Q1 | $86K | Sell |
18,791
-696,956
| -97% | -$2.8M | ﹤0.01% | 8497 |
|
|
2015
Q4 | $3.72M | Sell |
715,747
-477,869
| -40% | -$2.77M | ﹤0.01% | 2941 |
|
|
2015
Q3 | $7.22M | Buy |
1,193,616
+130,161
| +12% | +$1.6M | ﹤0.01% | 2195 |
|
|
2015
Q2 | $16.8M | Buy |
1,063,455
+349,996
| +49% | +$4.25M | 0.01% | 1479 |
|
|
2015
Q1 | $7.75M | Sell |
713,459
-271,978
| -28% | -$2.78M | ﹤0.01% | 2162 |
|
|
2014
Q4 | $10.4M | Buy |
985,437
+315,286
| +47% | +$3.08M | ﹤0.01% | 2004 |
|
|
2014
Q3 | $6.43M | Sell |
670,151
-213,754
| -24% | -$2.18M | ﹤0.01% | 2663 |
|
|
2014
Q2 | $10.2M | Buy |
883,905
+483,229
| +121% | +$4.4M | ﹤0.01% | 2102 |
|
|
2014
Q1 | $4.01M | Buy |
400,676
+242,917
| +154% | +$3.51M | ﹤0.01% | 3207 |
|
|
2013
Q4 | $2.05M | Buy |
157,759
+98,978
| +168% | +$1.36M | ﹤0.01% | 4227 |
|
|
2013
Q3 | $878K | Buy |
58,781
+19,514
| +50% | +$234K | ﹤0.01% | 5507 |
|
|
2013
Q2 | $367K | Buy |
+39,267
| New | +$266K | ﹤0.01% | 6498 |
|
Jeff Yass's RPTP Position: Q3 2016 in Review
Jeff Yass sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2016, closing a stake of 209,309 shares — an estimated $1.49M sold.
Jeff Yass first reported a position in RPTP in Q2 2013 and held it in 13 quarters. The position peaked at $16.8M in Q2 2015. 111 funds tracked by Wall St. Rank hold RPTP as of Q3 2016.
- Jeff Yass reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Jeff Yass sold 209,309 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2016, an estimated $1.49M.
- Jeff Yass first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Jeff Yass's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $16.8M in Q2 2015.
- 111 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2016.
Based on Susquehanna International Group's 13F filing for Q3 2016, filed 14 Nov 2016.